LEARNING ABOUT ALZHEIMER'S

THROUGH CLINICAL TRIALS

ABOUT ME

- General counsel and director of program development at Fox Hill Village, a CCRC
- Master's in health policy
- Fellow at the Green House® Project
- Advisor, Hastings Center, a bioethics research center
 - Aging, Chronic Conditions and Care Near End of Life Sector
- My father and father in law both lived with dementia

WHITE OAK COTTAGES



WHITE OAK COTTAGES

- Assisted living dementia residence on Fox Hill campus
- www.whiteoakcottages.com/blog-2/blog/
 - Green House adopter attempting to radically change the way long term care is provided
 - Focused on quality of life and autonomy of residents
 - 2 cottages, 12 private bedrooms in each

FAMILIES SEEKING ANSWERS

- Is there a cure in sight?
- What can I do to prevent or delay the onset of this disease?
- How can I better understand scientific findings in the news?

WHAT CAUSES ALZHEIMER'S?

- Still trying to understand what triggers the disease process
- Rift within research world as to which protein accumulation should be the focus of research
- Study of lifestyle giving some information about possible protections
- Epidemiology critical to developing and confirming hypotheses

WHAT IS EPIDEMIOLOGY?

- Medical detectives trying to discover what causes disease and effective treatments
- Study of disease patterns among populations
 - Who gets sick?
 - Where?
 - When?



HOW IT WORKS

- Data driven science
- Requires statistical analysis
- Iterative in nature
- Different tools depending on focus of study

OBSERVATION OF POPULATIONS

- Observational studies of past exposures to identify source of disease
 - May not understand how exposure causes the disease, but can lead to preventative measures
 - Develop a theory based on one case, or several cases
 - Review data to determine if they support hypothesis
 - John Snow 1854 cholera outbreak
 - AIDS 1980s
 - Zika

PROSPECTIVE TRACKING

- Cohort study usually focused on understanding influences on specific diseases
 - Population without disease
 - Track going forward
 - Questionnaires
 - Physical exams and/or specimens
 - Can include study of specific exposures/activities

EXAMPLES OF COHORT STUDIES

Framingham Heart Study: risk factors for heart disease

www.framinghamheartstudy.org

- 1948: 5200 subjects
- 1971 5124 subjects
- 2002
- Omni studies 1994 and 2003
- Nurses Health Studies: oral contraceptive study www.channing.harvard.edu
 - 1976: 238,000 subjects
 - 1989: second generation 116,000 subjects

CLINICAL TRIALS

- Clinical trials test the efficacy of potential treatments
- Epidemiology is essential component
- Phase I
 - Safety, small group of healthy volunteers
- Phase II
 - Dosage
 - Some measure of efficacy
 - Larger group with disease in question
- Phase III
 - Clinical trials with controls
 - Large groups, replications

CLINICAL TRIALS

- What is "gold standard"
 - Double blind
 - Placebo
 - Randomized
- Statistically significant outcomes
 - P value: probability that the effect observed could have happened by chance >.01 goal
- Peer Reviewed Publication
- Replication

APPLICATION TO ALZHEIMER'S

- Challenge of chronic disease investigation
 - Develops over many years
 - Likely to be result of multiple exposures
- Challenge of studying the brain
- Diagnosis not determinative without autopsy

SEARCHING FOR BIOMARKERS

- What are biomarkers?
 - Something that can be accurately and reliably measured to indicate presence of disease
 - Not yet
- "Hallmarks"?
 - Amyloid and tau build up
 - Shrinkage of hippocampus
- 2012: FDA approves Amyvid radioactive dye

VALIDATION ELUSIVE

- What FDA test suggested
- Led to realization that not everyone with Abeta had dementia;
- Some with dementia did not have Abeta
- Unresolved question of the role of Abeta and tau
- No scan test for Tau approved as of yet

CURRENT DRUG TRIALS

- Eli Lilly/ NIH Solanezumab A4 Study
- Eli Lilly/NIH LEARN Study
- Biogen Aducanumab Phase 1 → Phase III

SOLANEZUMAB

Solanezumab: The A4Study: Can early treatment prevent or delay onset of cognitive decline?

- Joint study by NIH and Eli Lilly
- Screening 10,000 people, 60 different sites
- Ages 65 to 85
- All have Abeta build up, but no cognitive issues yet
- Results must show improvement in cognition and function

LEARN TRIAL

What are the non-amyloid drivers of cognitive decline?

- Offshoot of the A4 Study
 - 500 subjects rejected from A4 due to no amyloid
- Testing efficacy of new testing protocols for A4
- Tau sub-study with tau imaging agent TBD
 - 150 subjects (50 from LEARN; 100 from A4)
- Results in 2020

ADUCANUMAB

- Biogen trial
- Phase I results in July 166 subjects
- Showed dose dependent response at high doses
- High levels of side effects
- Phase III results expected 2018

WHAT CAN WE DO TO PREVENT OR DELAY ONSET?

- Diet
- Sleep
- Exercise
- Mental stimulation
- Social engagement
- Stress management
- Avoidance of some medications
- What do the epidemiologists have to say?

BEYOND CURE: WHAT WILL PROTECT?

FOODS

- Chocolate
- Red wine
- Ginko balboa
- Cocoanut oil
- Mediterranean diet



HOW TO LOOK AT FOOD


- Who conducted trial?
- How many subjects?
- How was it structured?
 - Randomized, double blind, placebo
- How long did trial last?
- Published in a peer reviewed journal?
- Replicated?
- Real food equivalents?

Dosage calculation: how much food would you have to eat to get benefits described?

SUPPLEMENTS/LIFE STYLE


Prevagen

- Supplement not subject to FDA approval
- Cease and desist due to no clinical trial
 - 56 subjects
 - Self-reported results
- Class action suit



MENTAL STIMULATION

- Lumosity
 - Settlement with FTC for deceptive advertising
 - No credible trial showing improved general cognition



EXERCISE!

- Multiple studies suggesting exercise improves cognition
- Both in humans and animals
- Measured by either size of hippocampus or brain activity during mental exercise



DRILLING DOWN

APOE4 positive subjects

- Those who exercised regularly showed greater brain activity when performing mental exercise.
- Dose dependent
- 68 people aged 65 to 85
- Exercise self reported
- Brain activity measured by MRI
- P values < 0.033 and 0.014

Walking study of 120 cognitively intact people

- Aerobic exercise 4x/week vs. stretching exercises
- Measured size of hippocampus by MRI
- 2% increase in size in aerobic group, 1.4% decreased volume in stretching group
- P values <0.001

POTENTIALLY DANGEROUS DRUGS

- Several well designed studies show an association between long term use and an increased risk of dementia
- Not known why the drugs are linked with risk; could be circumstantial
- Provides tools for further study

POTENTIALLY DANGEROUS DRUGS

- Sedating and anti-nausea meds (Benadryl, Sominex, Dramamine)
- Followed 3500 people in Seattle health plan for 7 years
 - Had access to pharmacy records
 - Use of anti-cholinergics associated with development of dementia
 - P value < 0.001
 - Published in JAMA, March 2015
- Acid reflux medications (Prilosec, Nexium, Prevacid)
 - German study of 73,000 subjects over 7 years
 - 44% increase in development of dementia for those taking drugs for more than 18 months

ARE FEWER PEOPLE DEVELOPING DEMENTIA?

- Framingham Heart Study
 - 44% decline in rate since 1970s
 - Limited to those with a high school education
 - Better diet?
 - Meds for stroke and heart?
- Stay tuned!



INFORMATION ON CLINICAL TRIALS

- clinicaltrials.gov
- nia.nih.gov/alzheimers/clinical-trials
- http://www.alz.org/research/clinical_trials/clinical_trials_alzheimers.asp

SUMMING IT UP

- No drugs to cure, slow or delay in near future
- Pro-active steps may provide protection
 - Healthy diet
 - Exercise
 - Sleep
 - Cognitive reserve?
- Cautious use of other drugs
- What is good for the heart is good for the brain; data is suggesting that prevalence is dropping